» Articles » PMID: 9933442

Patients with Systemic Lupus Erythematosus (SLE) Have a Circulating Inducer of Interferon-alpha (IFN-alpha) Production Acting on Leucocytes Resembling Immature Dendritic Cells

Overview
Date 1999 Feb 5
PMID 9933442
Citations 75
Authors
Affiliations
Soon will be listed here.
Abstract

Patients with active SLE often have an ongoing production of IFN-alpha. We therefore searched for an endogenous IFN-alpha-inducing factor (IIF) in SLE patients and found that their sera frequently induced production of IFN-alpha in cultures of peripheral blood mononuclear cells (PBMC) from healthy blood donors, especially when the PBMC were costimulated with the cytokines IFN-alpha2b and granulocyte-macrophage colony-stimulating factor (GM-CSF). The phenotype of the IFN-alpha-producing cells (IPC) as determined by flow cytometry corresponded to that of the natural IPC, resembling immature dendritic cells. The IIF activity in SLE sera was sometimes as high as that of a virus and was present especially in patients with active disease and with measurable IFN-alpha levels in serum. The IIF had an apparent molecular weight of 300-1000 kD and appeared to consist of both immunoglobulin and DNA, possibly being immune complexes. This endogenous IFN-alpha inducer may be of pathogenic significance, since a reported occasional adverse effect of IFN-alpha therapy in patients with non-autoimmune disorders is development of anti-dsDNA antibodies and SLE.

Citing Articles

Type I Interferons in Systemic Autoimmune Rheumatic Diseases: Pathogenesis, Clinical Features and Treatment Options.

Drougkas K, Skarlis C, Mavragani C Mediterr J Rheumatol. 2024; 35(Suppl 2):365-380.

PMID: 39193187 PMC: 11345602. DOI: 10.31138/mjr.270324.tis.


Potential role of EBV and Toll-like receptor 9 ligand in patients with systemic lupus erythematosus.

Izadi S, Najfizadeh S, Nejati A, TeimooriRad M, Shahmahmoodi S, Shirazi F Immunol Res. 2023; 71(5):698-708.

PMID: 37097524 DOI: 10.1007/s12026-023-09380-6.


Emerging concepts of type I interferons in SLE pathogenesis and therapy.

Psarras A, Wittmann M, Vital E Nat Rev Rheumatol. 2022; 18(10):575-590.

PMID: 36097207 DOI: 10.1038/s41584-022-00826-z.


Role of the innate and adaptive immune responses in the pathogenesis of systemic lupus erythematosus.

Bolouri N, Akhtari M, Farhadi E, Mansouri R, Faezi S, Jamshidi A Inflamm Res. 2022; 71(5-6):537-554.

PMID: 35298669 DOI: 10.1007/s00011-022-01554-6.


The Role of Clinical Features and Serum Biomarkers in Identifying Patients with Incomplete Lupus Erythematosus at Higher Risk of Transitioning to Systemic Lupus Erythematosus: Current Perspectives.

Sternhagen E, Bettendorf B, Lenert A, Lenert P J Inflamm Res. 2022; 15:1133-1145.

PMID: 35210816 PMC: 8863324. DOI: 10.2147/JIR.S275043.


References
1.
Zhou L, Schwarting R, Smith H, Tedder T . A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily. J Immunol. 1992; 149(2):735-42. View

2.
Bombardier C, Gladman D, Urowitz M, Caron D, Chang C . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992; 35(6):630-40. DOI: 10.1002/art.1780350606. View

3.
Ronnblom L, Alm G, Oberg K . Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med. 1990; 227(3):207-10. DOI: 10.1111/j.1365-2796.1990.tb00144.x. View

4.
Cederblad B, Alm G . Interferons and the colony-stimulating factors IL-3 and GM-CSF enhance the IFN-alpha response in human blood leucocytes induced by herpes simplex virus. Scand J Immunol. 1991; 34(5):549-55. DOI: 10.1111/j.1365-3083.1991.tb01578.x. View

5.
Ronnblom L, Alm G, Oberg K . Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med. 1991; 115(3):178-83. DOI: 10.7326/0003-4819-115-3-178. View